Kite Pharma, Amgen deal
Amgen will use Kite’s engineered autologous cell therapy (eACT) platform to develop chimeric antigen receptor (CAR) T cell therapies against Amgen’s cancer targets. The companies will form a joint steering committee to oversee development of the programs. Each company will own exclusive, worldwide rights to certain programs, which are based on targets selected by Kite and Amgen. Kite will conduct preclinical development, and Amgen will fund R&D costs for all programs through an IND filing. The companies will then be responsible for funding, developing and commercializing programs their respective programs. Kite will reimburse Amgen for R&D costs through an IND filing for Kite’s programs. Kite is also responsible for the manufacturing and processing of Amgen’s programs for a certain period following the completion of Phase II trials. ...